Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

Novartis recently announced that it will acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company. The acquisition will add abelacimab ...

despite a mid-stage stroke trial miss – as well as Anthos Therapeutics with abelacimab, an injectable Factor XI/XIa-targeting antibody that generated encouraging results in a phase 2b trial ...

as well as Anthos Therapeutics with abelacimab, an injectable Factor XI/XIa-targeting antibody that generated encouraging results in a phase 2b trial earlier this year. Milvexian is in three late ...

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...

Elliott urges Germany's RWE to 'significantly' hike share buyback Activist investor Elliott (ECAL.UL) disclosed a stake of close to 5% in Germany's biggest utility RWE on Monday and urged it to ...

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United ...

Sanofi is paying a hefty $600 million up front, and milestone payments to come could add up to $1.3 billion. Black Diamond Therapeutics Inc. is getting $70 million up front and could earn up to $710 ...